DICE Therapeutics

DICE Therapeutics is a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates for the treatment of chronic diseases in immunology and other therapeutic areas. We are initially focused on developing oral therapies targeting well-validated points in immunology, aiming to achieve efficacy comparable to their systemic biological counterparts, which have demonstrated the greatest therapeutic benefits to date in these disease areas. Our platform, which we call DELSCAPE, is designed to discover selective orally available small molecules with the potential to modulate protein-protein interactions (PPI) as effectively as systemic biologics. We believe there is a significant unmet medical need for convenient oral therapies for chronic immune-mediated diseases that can deliver the therapeutic benefits of systemic biologics. We are utilizing our proprietary DELSCAPE platform to design and develop a range of oral small molecule therapies targeting validated biological targets to address chronic diseases in immunology and other therapeutic areas.